Last reviewed · How we verify

NCT05809271

Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

Completed Phase 1 Last updated 19 March 2025
What this trial tests

Phase 1 trial testing MDMA 120 mg + MDMA 60 mg in Healthy in 25 participants. Completed in 7 March 2025.

Timeline
17 November 2023
Primary endpoint
7 March 2025
7 March 2025

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment25
Start date17 November 2023
Primary completion7 March 2025
Estimated completion7 March 2025
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. The current study investigates differences in duration of acute effects and side effects after administration of a single dose of MDMA compared to a repeated administration.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Can research on entactogens contribute to a deeper understanding of human sexuality?
    Holka-Pokorska J. · · 2023 · cited 4× · PMID 37935915 · DOI 10.1007/s43440-023-00552-7

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing